seung-won choi

Columbia University
New York, New York, United States

Seung Won Choi, M.D. PhD.

I'm a postdoctoral research scientist in the Department of Systems Biology at Columbia University. Originally a board-certified neurosurgeon from South Korea (subspecialty in brain tumor), my journey led me to a deep-seated passion for precision oncology in glioma patients.
Currently, I'm immersed in a groundbreaking project—building a virtual community of patients using multi-omics data from clinical trials. This endeavor represents not just scientific innovation but a beacon of hope for those battling glioma-related challenges.

Contact information
E-mail : sc5006@cumc.columbia.edu

Education
2016-2019 Ph. D. in Health Science and Technology, Sungkyunkwan University
2003- 2009 M.D. Ewha Womans University College of Medicine

Clinical experience
2019~2021 Clinical Fellow, Department of Neurosurgery, Samsung Medical Center (Subspecialty in Brain tumor)
2015-2016 Clinical Fellow, Department of Pediatric Neurosurgery, Asan Medical Center
2010-2013 Resident, Department of Neurosurgery, Asan Medical Center


Awards
- Academic award (Best paper in basic science), The Korean Brain Tumor Society, 2020
- Academic award (Best paper in basic science), The Korean Neurosurgical Society, 2020

Experience in Clinical trials
1. GC1118 in recurrent glioblastoma patients with high EGFR amplification (NCT03618667)
2. A explorative study to evaluate the clinical feasibility of AVATAMED (NCT04313842)


Selected papers
1. A Multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification, Cancer Medicine. 2023, August (Co-First)
2. Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma, Cell Death & Disease. 2021, April 07;12(4):374 (Co-first)
3. Hypermuagenesis in untreated adult gliomas due to inherited mismatch mutations, Int J Cancer. 2019 Jun 15;144(12):3023-3030. (Co-first)
4. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy,Nat Genet. 2018 Oct;50(10):1399-1411. (Co-author)
5. Spatiotemporal genomic architecture informs precision oncology in glioblastoma, Nat Genet. 2017 Apr;49(4):595-599. (Co-author)